Currently, CNMD's trailing twelve months (TTM) EPS stands at $1.77, according to the most recent financial reports. In 2025, CNMD reported a per-share earnings of $1.52, which represents a decrease compared to the EPS of $4.29 recorded in 2024. CNMD recorded an EPS of $0.45 for the quarterly period ending on Mar 31, 2026.
In 2025, CONMED's EPS was $1.52, a decrease of 64.6% from $4.29 in 2024. For the quarter ending Mar 31, 2026, the EPS was $0.45, reflecting a 136.8% increase compared to the same quarter a year earlier. The trailing twelve months (TTM) EPS as of March 2026 is $1.77. In 2024, the annual EPS was $4.29, showing an increase of 104.3% compared to 2023.
CONMED has recorded a growth in earnings per share of 136.8% over the past 12 months (YoY, quarterly). CONMED had an average annual EPS growth of 35.7% over the last five years. Over the last decade, CNMD had an average annual earnings per share growth of 3.3%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| BSX Boston Scientific Corp | 18.72 | 55.6% | 63.3% | N/A |
| CNMD CONMED Corp | 19.01 | -64.6% | N/A | 35.7% |
| MDT Medtronic plc | 21.39 | 3.3% | 9.8% | 6.9% |
| JNJ Johnson & Johnson | 27.02 | 90.6% | 17.7% | 14.8% |
| SYK Stryker Corp | 35.26 | 8% | 10.9% | 14.8% |
| TFX Teleflex Inc | N/A | -1,462.4% | N/A | N/A |
| IART Integra Lifesciences Holdings Corp | N/A | -7,388.9% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.